首页> 外文OA文献 >Correction to: Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker‑Driven Phase III Trial

【2h】

Correction to: Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker‑Driven Phase III Trial

机译：纠正：生物标志物驱动阶段试验的研究设计和样本量的最佳决策标准

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Akira Takazawa; Satoshi Morita;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Optimal sample size allocation and go/no‐go decision rules for phase II/III programs where several phase III trials are performed [J] . Preussler Stella, Kieser Meinhard, Kirchner Marietta Biometrical Journal . 2019,第2期

机译：阶段II / III计划的最佳样本大小分配和GO / NO-GO决策规则进行了几阶段III试验
2. Intermediate Monitoring, Sample Size Reassessment, and Multi-Treatment Optimal Response-Adaptive Designs for Phase III Clinical Trials with More Than One Constraint [J] . ATANU BISWAS, PINAKPANI PAL Communications in Statistics . 2009,第6a7期

机译：具有多个约束的III期临床试验的中间监测，样本量重新评估和多治疗最佳反应适应性设计
3. Intermediate Monitoring, Sample Size Reassessment, and Multi-Treatment Optimal Response-Adaptive Designs for Phase III Clinical Trials with More Than One Constraint [J] . Atanu Biswas Communications in Statistics - Simulation and Computation . 2009,第6期

机译：具有多个约束的III期临床试验的中间监测，样本量重新评估和多治疗最佳反应适应性设计
4. A HIGHLY SELECTIVE AND SENSITIVE LC-MS/HRMS ASSAY FOR COPORPORPHYRIN-I AND -III, EMERGING ENDOGENOUS BIOMARKERS OF OATP, IN FIRST-IN-HUMAN CLINICAL TRIALS [C] . Ragu Ramanathan, Amanda King-Ahmad, Christopher L. Holliman, International Mass Spectrometry Conference . 2018

机译：用于Coporporphyrin-I和-III的高度选择性和敏感的LC-MS / HRMS测定，oATP的新出现的oATP内源性生物标志物，在一中的临床试验中
5. Rapid Enrollment Design for Finding the Optimal Dose in Immunotherapy Trials with Ordered Groups and Optimal Design of Experiments with Observation Censoring Driven by Random Enrollment [D] . Xue, Xiaoqiang 2019

机译：在有序组的免疫治疗试验中寻找最佳剂量的快速入组设计，以及随机入组驱动的观察检查实验的优化设计
6. MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial [O] . Claire Matthews, Carol Freeman, Linda D Sharples, 2019

机译：MesoTRAP：一项可行性研究包括一项试验性临床试验该试验比较了由于恶性胸膜间皮瘤而在被困肺部患者中采用视频辅助胸腔镜部分胸膜切除术与留置胸膜导管进行胸膜肺切除术旨在解决III期临床试验的募集和随机性不确定性以及样本量要求
7. Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1 [O] . Miranta Antoniou, Ruwanthi Kolamunnage-Dona, Andrea Jorgensen 2018

机译：纠正：安东尼，M。;等等。生物标记导向II期和第三阶段的非适应试验设计：方法论审查。 J. PERS。 Med。 2017,7,11

Correction to: Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker‑Driven Phase III Trial

著录项

引文网络

相似文献

相关主题

期刊订阅